clofarabine (IV formulation)

DRUG5 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Acute Myelogenous LeukemiaLeukemia, Lymphoblastic, Acute, PediatricLeukemia, Lymphocytic, Acute, AdultLeukemia, Lymphocytic, Acute, PediatricLeukemia, Myelocytic, Acute, AdultLeukemia, Myelocytic, Acute, PediatricMyelodysplastic Syndromes, AdultSolid Tumors

Phase 1

Clofarabine in Adult Patients With Advanced Solid Tumors

CompletedNCT00125840

Genzyme, a Sanofi CompanyLeukemia, Lymphocytic, Acute, Adult, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Myelocytic, Acute, Adult +3

Start: 2002-08-31End: 2007-08-31Updated: 2014-02-05

Phase 2

Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)

CompletedNCT00042341

Genzyme, a Sanofi CompanyLeukemia, Lymphoblastic, Acute, Pediatric

Start: 2002-05-31End: 2006-01-31Target: 60Updated: 2022-05-27

Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

CompletedNCT00042354

Genzyme, a Sanofi CompanyLeukemia, Myelocytic, Acute, Pediatric

Start: 2002-05-31End: 2004-08-31Target: 40Updated: 2015-03-05

Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia

CompletedNCT00044889

Genzyme, a Sanofi CompanyAcute Myelogenous Leukemia

Start: 2002-05-31End: 2003-03-31Target: 40Updated: 2014-03-19

Phase 3

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

CompletedNCT00317642

Genzyme, a Sanofi CompanyAcute Myelogenous Leukemia

Start: 2006-08-31End: 2012-01-31Updated: 2014-04-14